サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1132309

癌遺伝子治療市場のシェア・規模・動向・産業分析・予測 (2022年～2030年)：治療法 (腫瘍溶解性ウイルス療法・遺伝子導入)・エンドユーザー (研究機関・バイオ医薬品企業)・地域別

Cancer Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Therapy (Oncolytic Virotherapy, Gene Transfer); By End-Use (Research Institutes, Biopharma Companies); By Region; Segment Forecast, 2022 - 2030
出版日: | 発行: Polaris Market Research | ページ情報: 英文 112 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
癌遺伝子治療市場のシェア・規模・動向・産業分析・予測 (2022年～2030年)：治療法 (腫瘍溶解性ウイルス療法・遺伝子導入)・エンドユーザー (研究機関・バイオ医薬品企業)・地域別
出版日: 2022年09月01日
発行: Polaris Market Research
ページ情報: 英文 112 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の癌遺伝子治療の市場規模は2030年には39億9,000万米ドルの規模に成長すると予測されています。

当レポートでは、世界の癌遺伝子治療の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の癌遺伝子治療市場の洞察

  • 癌遺伝子治療：産業のスナップショット
  • 癌遺伝子治療：市場力学
    • 成長推進因子・機会
    • 成長抑制因子・課題
  • ポーターのファイブフォース分析
  • PESTLE分析
  • 癌遺伝子治療産業の動向
  • バリューチェーン分析
  • COVID-19：影響分析

第5章 世界の癌遺伝子治療市場：治療法別

  • 主な調査結果
  • 腫瘍溶解性ウイルス療法
  • 遺伝子誘導免疫療法
  • 遺伝子導入

第6章 世界の癌遺伝子治療市場：エンドユーザー別

  • 主な調査結果
  • 病院
  • 研究機関
  • バイオ医薬品企業
  • 診断センター
  • その他

第7章 世界の癌遺伝子治療市場：地域別

  • 主な調査結果
  • 北米
  • 欧州
  • アジア太平洋
  • 中東・アフリカ
  • ラテンアメリカ

第8章 競合情勢

  • 拡張・買収の分析
  • 提携・協力・合意・展示会

第9章 企業プロファイル

  • Altor Bioscience Corporation
  • SiBiono
  • Shanghai Sunway Biotech Company Limited
  • BioCancell, GlobeImmune, Inc
  • Aduro Biotech
  • OncoGeneX
  • New Link Genetics
  • ZioPharm Oncology
  • Genelux Corporation
  • Novartis AG
  • GlaxoSmithKline PLC（GSK）
  • Amgen, Inc
  • Bristol Myers
  • Squibb Company
  • Karyopharm Therapeutics, Inc
  • Gilead Sciences, Inc
  • Adaptimmune Limited
  • Sarepta Therapeutics, Inc
  • Biogen
  • Orchard Therapeutics Plc
  • Spark Therapeutics, Inc
  • AGC Biologics, Anges, Inc
  • Bluebird Bio, Inc
  • Jazz Pharmaceuticals Inc
  • Dynavax Technologies
  • Human Stem Cells Institute
  • Uniqure N.V.
  • Gensight Biologics
  • Celgene Corporation
  • Cellectis
  • Merck KGaA, AstraZeneca Plc
  • AstraZeneca Plc
  • BIOCAD
  • Crinetics Pharmaceuticals, Inc
  • EffRx Pharmaceuticals S.A
  • Euroscreen S.A
  • Vicore Pharma AB
  • Cell Genesys Inc
  • Achieve Life Science Inc
  • Advantagene Inc
  • GenVec Inc.
図表

List of Tables

  • Table 1 Global Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 2 Global Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 3 Cancer Gene Therapy Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 4 North America: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 5 North America: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 6 U.S.: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 7 U.S.: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 8 Canada: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 9 Canada: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 10 Europe: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 11 Europe: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 12 UK: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 13 UK: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 14 France: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 15 France: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 16 Germany: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 17 Germany: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 18 Italy: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 19 Italy: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 20 Spain: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 21 Spain: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 22 Netherlands: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 23 Netherlands: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 24 Russia: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 25 Russia: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 26 Asia Pacific: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 27 Asia Pacific: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 28 China: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 29 China: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 30 India: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 31 India: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 32 Malaysia: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 33 Malaysia: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 34 Japan: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 35 Japan: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 36 Indonesia: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 37 Indonesia: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 38 South Korea: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 39 South Korea: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 40 Middle East & Africa: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 41 Middle East & Africa: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 42 Saudi Arabia: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 43 Saudi Arabia: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 44 UAE: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 45 UAE: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 46 Israel: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 47 Israel: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 48 South Africa: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 49 South Africa: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 50 Latin America: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 51 Latin America: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 52 Mexico: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 53 Mexico: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 54 Brazil: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 55 Brazil: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • Table 56 Argentina: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 57 Argentina: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)

List of Figures

Figure 1 Global Cancer Gene Therapy Market, 2018 - 2030 (USD Billion)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top-Down & Bottom-Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by End-Use

Figure 7 Global Cancer Gene Therapy Market, by End-Use, 2021 & 2030 (USD Billion)

Figure 8 Market by Therapy

Figure 9 Global Cancer Gene Therapy Market, by Therapy, 2021 & 2030 (USD Billion)

Figure 10 Cancer Gene Therapy Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 11 Strategic Analysis - Cancer Gene Therapy Market

目次
Product Code: PM2588

The global cancer gene therapy market size is expected to reach USD 3.99 billion by 2030, according to a new study by Polaris Market Research. The report "Cancer Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Therapy (Oncolytic Virotherapy, Gene Transfer); By End-Use (Research Institutes, Biopharma Companies); By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides an analysis of future market growth.

The growing demand for cancer gene therapy in diagnosing diseases is expected to drive industry growth. Furthermore, increasing investment in R&D, technological advancement, well-established infrastructure, and awareness among the people are the major factors driving the demand.

In addition, the growing geriatric population across the countries such as India, Japan, the U.S., and China is likely to positively impact the demand for the treatment over the coming years. Furthermore, with the rising technological advancement in the medical sector with government initiatives, the industry is expected to expand.

The industry was negatively impacted during the COVID-19 pandemic. Hospitals were made available for COVID-19 treatment, thus resulting in the declination of industry, but post-pandemic, it is expected to grow.

Cancer Gene Therapy Market Report Highlights

The demand for the treatment in many regions is increasing, with a higher success rate in clinical and preclinical trails.

Cancer treatment is advancing over the period with a higher success rate and is gaining demand with increasing healthcare awareness among the people.

Cancer gene-induced immunotherapy dominated the segment with a higher revenue share in 2021 and is anticipated to grow during forecast period with increased funding in R&D and advancements in technology.

In the end-use of product, hospitals dominate the market with a higher share owing to the developed infrastructure and the demand for treatment available under one roof.

North America dominates the market with the highest revenue share. It is expected to expand during the forecast period with the availability of well-established infrastructure, funding in R&D, and technological advancement.

Major players operating in the industry include BioCancell, GlobeImmune, Inc., Aduro Biotech, ZioPharm Oncology, Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Sarepta Therapeutics, Inc, Biogen, Orchard Therapeutics Plc.

Polaris Market Research has segmented the cancer gene therapy market report based on therapy, end-use, and region:

Cancer Gene Therapy, Therapy Outlook (Revenue - USD Billion, 2018 - 2030)

Oncolytic Virotherapy

Gene-induced Immunotherapy

Gene transfer

Cancer Gene Therapy, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospitals

Research Institutes

Biopharma Companies

Diagnostic centers

Others

Cancer Gene Therapy, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Cancer Gene Therapy Market Insights

  • 4.1. Cancer Gene Therapy Market - Industry Snapshot
  • 4.2. Cancer Gene Therapy Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Improving regulatory scenario has surged the cancer gene therapy market
      • 4.2.1.2. Increase in the number of research and development activities
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost involved in gene therapy
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Cancer Gene Therapy Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Cancer Gene Therapy Market, by Therapy

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Cancer Gene Therapy, by Therapy, 2018 - 2030 (USD Billion)
  • 5.3. Oncolytic Virotherapy
    • 5.3.1. Global Cancer Gene Therapy Market, by Oncolytic Virotherapy, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Gene-induced Immunotherapy
    • 5.4.1. Global Cancer Gene Therapy Market, by Gene-induced Immunotherapy, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Gene transfer
    • 5.5.1. Global Cancer Gene Therapy Market, by Gene transfer, by Region, 2018 - 2030 (USD Billion)

6. Global Cancer Gene Therapy Market, by End-Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
  • 6.3. Hospitals
    • 6.3.1. Global Cancer Gene Therapy Market, by Hospitals, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Research Institutes
    • 6.4.1. Global Cancer Gene Therapy Market, by Research Institutes, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Biopharma Companies
    • 6.5.1. Global Cancer Gene Therapy Market, by Biopharma Companies, by Region, 2018 - 2030 (USD Billion)
  • 6.6. Diagnostic centers
    • 6.6.1. Global Cancer Gene Therapy Market, by Diagnostic centers, by Region, 2018 - 2030 (USD Billion)
  • 6.7. Others
    • 6.7.1. Global Cancer Gene Therapy Market, by Others, by Region, 2018 - 2030 (USD Billion)

7. Global Cancer Gene Therapy Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Cancer Gene Therapy Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 7.3. Cancer Gene Therapy Market - North America
    • 7.3.1. North America: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.3.2. North America: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.3.3. Cancer Gene Therapy Market - U.S.
      • 7.3.3.1. U.S.: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.3.3.2. U.S.: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.3.4. Cancer Gene Therapy Market - Canada
      • 7.3.4.1. Canada: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.3.4.2. Canada: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • 7.4. Cancer Gene Therapy Market - Europe
    • 7.4.1. Europe: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.4.2. Europe: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.4.3. Cancer Gene Therapy Market - UK
      • 7.4.3.1. UK: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.3.2. UK: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.4.4. Cancer Gene Therapy Market - France
      • 7.4.4.1. France: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.4.2. France: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.4.5. Cancer Gene Therapy Market - Germany
      • 7.4.5.1. Germany: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.5.2. Germany: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.4.6. Cancer Gene Therapy Market - Italy
      • 7.4.6.1. Italy: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.6.2. Italy: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.4.7. Cancer Gene Therapy Market - Spain
      • 7.4.7.1. Spain: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.7.2. Spain: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.4.8. Cancer Gene Therapy Market - Netherlands
      • 7.4.8.1. Netherlands: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.8.2. Netherlands: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.4.9. Cancer Gene Therapy Market - Russia
      • 7.4.9.1. Russia: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.4.9.2. Russia: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • 7.5. Cancer Gene Therapy Market - Asia Pacific
    • 7.5.1. Asia Pacific: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.5.2. Asia Pacific: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.5.3. Cancer Gene Therapy Market - China
      • 7.5.3.1. China: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.3.2. China: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.5.4. Cancer Gene Therapy Market - India
      • 7.5.4.1. India: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.4.2. India: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.5.5. Cancer Gene Therapy Market - Malaysia
      • 7.5.5.1. Malaysia: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.5.2. Malaysia: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.5.6. Cancer Gene Therapy Market - Japan
      • 7.5.6.1. Japan: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.6.2. Japan: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.5.7. Cancer Gene Therapy Market - Indonesia
      • 7.5.7.1. Indonesia: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.7.2. Indonesia: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.5.8. Cancer Gene Therapy Market - South Korea
      • 7.5.8.1. South Korea: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.5.8.2. South Korea: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • 7.6. Cancer Gene Therapy Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.6.2. Middle East & Africa: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.6.3. Cancer Gene Therapy Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.6.4. Cancer Gene Therapy Market - UAE
      • 7.6.4.1. UAE: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.4.2. UAE: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.6.5. Cancer Gene Therapy Market - Israel
      • 7.6.5.1. Israel: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.5.2. Israel: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.6.6. Cancer Gene Therapy Market - South Africa
      • 7.6.6.1. South Africa: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.6.6.2. South Africa: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
  • 7.7. Cancer Gene Therapy Market - Latin America
    • 7.7.1. Latin America: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
    • 7.7.2. Latin America: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.7.3. Cancer Gene Therapy Market - Mexico
      • 7.7.3.1. Mexico: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.7.3.2. Mexico: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.7.4. Cancer Gene Therapy Market - Brazil
      • 7.7.4.1. Brazil: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.7.4.2. Brazil: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)
    • 7.7.5. Cancer Gene Therapy Market - Argentina
      • 7.7.5.1. Argentina: Cancer Gene Therapy Market, by End-Use, 2018 - 2030 (USD Billion)
      • 7.7.5.2. Argentina: Cancer Gene Therapy Market, by Therapy, 2018 - 2030 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Altor Bioscience Corporation
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. SiBiono
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Shanghai Sunway Biotech Company Limited
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. BioCancell, GlobeImmune, Inc
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Aduro Biotech
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. OncoGeneX
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. New Link Genetics
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. ZioPharm Oncology
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Genelux Corporation
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Novartis AG
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. GlaxoSmithKline PLC (GSK)
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Amgen, Inc
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Bristol Myers
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Squibb Company
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Karyopharm Therapeutics, Inc
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Gilead Sciences, Inc
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Adaptimmune Limited
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development
  • 9.18. Sarepta Therapeutics, Inc
    • 9.18.1. Company Overview
    • 9.18.2. Financial Performance
    • 9.18.3. Product Benchmarking
    • 9.18.4. Recent Development
  • 9.19. Biogen
    • 9.19.1. Company Overview
    • 9.19.2. Financial Performance
    • 9.19.3. Product Benchmarking
    • 9.19.4. Recent Development
  • 9.20. Orchard Therapeutics Plc
    • 9.20.1. Company Overview
    • 9.20.2. Financial Performance
    • 9.20.3. Product Benchmarking
    • 9.20.4. Recent Development
  • 9.21. Spark Therapeutics, Inc
    • 9.21.1. Company Overview
    • 9.21.2. Financial Performance
    • 9.21.3. Product Benchmarking
    • 9.21.4. Recent Development
  • 9.22. AGC Biologics, Anges, Inc
    • 9.22.1. Company Overview
    • 9.22.2. Financial Performance
    • 9.22.3. Product Benchmarking
    • 9.22.4. Recent Development
  • 9.23. Bluebird Bio, Inc
    • 9.23.1. Company Overview
    • 9.23.2. Financial Performance
    • 9.23.3. Product Benchmarking
    • 9.23.4. Recent Development
  • 9.24. Jazz Pharmaceuticals Inc
    • 9.24.1. Company Overview
    • 9.24.2. Financial Performance
    • 9.24.3. Product Benchmarking
    • 9.24.4. Recent Development
  • 9.25. Dynavax Technologies
    • 9.25.1. Company Overview
    • 9.25.2. Financial Performance
    • 9.25.3. Product Benchmarking
    • 9.25.4. Recent Development
  • 9.26. Human Stem Cells Institute
    • 9.26.1. Company Overview
    • 9.26.2. Financial Performance
    • 9.26.3. Product Benchmarking
    • 9.26.4. Recent Development
  • 9.27. Uniqure N.V.
    • 9.27.1. Company Overview
    • 9.27.2. Financial Performance
    • 9.27.3. Product Benchmarking
    • 9.27.4. Recent Development
  • 9.28. Gensight Biologics
    • 9.28.1. Company Overview
    • 9.28.2. Financial Performance
    • 9.28.3. Product Benchmarking
    • 9.28.4. Recent Development
  • 9.29. Celgene Corporation
    • 9.29.1. Company Overview
    • 9.29.2. Financial Performance
    • 9.29.3. Product Benchmarking
    • 9.29.4. Recent Development
  • 9.30. Cellectis
    • 9.30.1. Company Overview
    • 9.30.2. Financial Performance
    • 9.30.3. Product Benchmarking
    • 9.30.4. Recent Development
  • 9.31. Merck KGaA, AstraZeneca Plc
    • 9.31.1. Company Overview
    • 9.31.2. Financial Performance
    • 9.31.3. Product Benchmarking
    • 9.31.4. Recent Development
  • 9.32. AstraZeneca Plc
    • 9.32.1. Company Overview
    • 9.32.2. Financial Performance
    • 9.32.3. Product Benchmarking
    • 9.32.4. Recent Development
  • 9.33. BIOCAD
    • 9.33.1. Company Overview
    • 9.33.2. Financial Performance
    • 9.33.3. Product Benchmarking
    • 9.33.4. Recent Development
  • 9.34. Crinetics Pharmaceuticals, Inc
    • 9.34.1. Company Overview
    • 9.34.2. Financial Performance
    • 9.34.3. Product Benchmarking
    • 9.34.4. Recent Development
  • 9.35. EffRx Pharmaceuticals S.A
    • 9.35.1. Company Overview
    • 9.35.2. Financial Performance
    • 9.35.3. Product Benchmarking
    • 9.35.4. Recent Development
  • 9.36. Euroscreen S.A
    • 9.36.1. Company Overview
    • 9.36.2. Financial Performance
    • 9.36.3. Product Benchmarking
    • 9.36.4. Recent Development
  • 9.37. Vicore Pharma AB
    • 9.37.1. Company Overview
    • 9.37.2. Financial Performance
    • 9.37.3. Product Benchmarking
    • 9.37.4. Recent Development
  • 9.38. Cell Genesys Inc
    • 9.38.1. Company Overview
    • 9.38.2. Financial Performance
    • 9.38.3. Product Benchmarking
    • 9.38.4. Recent Development
  • 9.39. Achieve Life Science Inc
    • 9.39.1. Company Overview
    • 9.39.2. Financial Performance
    • 9.39.3. Product Benchmarking
    • 9.39.4. Recent Development
  • 9.40. Advantagene Inc
    • 9.40.1. Company Overview
    • 9.40.2. Financial Performance
    • 9.40.3. Product Benchmarking
    • 9.40.4. Recent Development
  • 9.41. GenVec Inc.
    • 9.41.1. Company Overview
    • 9.41.2. Financial Performance
    • 9.41.3. Product Benchmarking
    • 9.41.4. Recent Development